Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin
about
Melanoma: from melanocyte to genetic alterations and clinical optionsResistant mechanisms to BRAF inhibitors in melanomaRecent advances in molecular genetics of melanoma progression: implications for diagnosis and treatmentClinical utility of nivolumab in the treatment of advanced melanomaUpdates in Therapy for Advanced MelanomaMelanoma: oncogenic drivers and the immune systemPathways and therapeutic targets in melanomaCIViC databaseFunction and Clinical Implications of Long Non-Coding RNAs in Melanoma.The next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy responseExtracutaneous melanomas: a primer for the radiologist.Discrepant alterations in main candidate genes among multiple primary melanomasUsing high-throughput sequencing transcriptome data for INDEL detection: challenges for cancer drug discovery.Beyond histology: translating tumor genotypes into clinically effective targeted therapies.Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignanciesImatinib: a breakthrough of targeted therapy in cancer.Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trialBreathing new life into immunotherapy: review of melanoma, lung and kidney cancerUnderstanding the biology of melanoma and therapeutic implicationsPossible prognostic and therapeutic significance of c-Kit expression, mast cell count and microvessel density in renal cell carcinoma.GNAQ mutation in a patient with metastatic mucosal melanoma.Resistance to c-Kit inhibitors in melanoma: insights for future therapiesGenotyping of cutaneous melanoma.Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06).Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanomaCombining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment.Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanomaRSK1 activation promotes invasion in nodular melanoma.Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factorsGastrointestinal Stromal Tumors (GIST): A Prospective Analysis and an Update on Biomarkers and Current Treatment Concepts.Cost Effectiveness of Sequencing 34 Cancer-Associated Genes as an Aid for Treatment Selection in Patients with Metastatic Melanoma.Sunrise in melanoma management: Time to focus on melanoma burden in Asia.Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT InhibitionOncogenic KIT mutations in different exons lead to specific changes in melanocyte phospho-proteome.Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA.Extraction and analysis of signatures from the Gene Expression Omnibus by the crowd.Sequential Combination Chemotherapy of Dacarbazine (DTIC) with Carboplatin and Paclitaxel for Patients with Metastatic Mucosal Melanoma of Nasal Cavity and Paranasal Sinuses.Clinics, prognosis and new therapeutic options in patients with mucosal melanoma: A retrospective analysis of 75 patients.Mitigating the toxic effects of anticancer immunotherapy.Non-BRAF targeted therapies for melanoma: protein kinase inhibitors in Phase II clinical trials.
P2860
Q21284811-C562F98C-D36E-490B-95F9-5943096A77BAQ26739717-6F694341-B6A9-469B-ACE4-205DE16C9D66Q26740631-1B5B7D28-E93B-472F-B5C7-6425EB0A8F22Q26751268-DEFBBD76-F84A-48B1-94F1-B1ED15B6B87EQ26771119-F3994698-16FA-45A0-9D9F-A6223EAAC475Q26775598-A2FDA88F-3699-43B3-BC3F-9F5CBC6BAEE0Q26865736-F8C4B66C-AE4F-49C9-A873-E287560BBC99Q27612411-FF75A27D-C278-437A-82AE-B5649E43842DQ30313298-60D8B645-753D-4207-98C6-C7D5B7BC9FEAQ30384301-4FF84787-219A-428F-85D2-00794413A1C6Q30397680-7B20F943-33E8-4EDB-96A7-F41E41F49750Q30578299-41BD8D37-974C-4BA5-B91E-7280AD96369EQ31038214-6632405C-5206-42CB-AFD8-F8A9B4CFB1DAQ33560928-E815B019-F1B2-454D-ACF3-D445C565092DQ33572971-B96DA832-DACD-42C4-9798-25E051DCC2DAQ33747261-C46D9A48-6136-42B6-ABA9-C0D284C4E44FQ33749057-B877C21D-0450-485E-A80D-1704917035B6Q33862861-D4917F2E-0965-4DDB-B8F9-60FD0CD73F3BQ33978378-605167B4-7038-4FC7-B183-031DD7159AB1Q34072594-86A708EA-4D25-41D1-B48D-EFC06C245E10Q34467908-6C634B12-E347-4A18-AEE5-30000CB51CE1Q34667532-B9F295CD-FB98-4048-8350-F18AE3CE799BQ34667738-0EC50BAB-ACF3-4C91-9161-D9572CE2CE9EQ34673458-FA94DDE3-E5D7-4E60-A723-7D3FFAA743F1Q34898560-43377378-5328-4312-8E73-D7516D807964Q35063621-1A97E202-E2C9-4A04-A8B3-E3AFFAEC87E7Q35093281-CDF4D905-BF67-4100-9AD5-A49E51D13460Q35143744-AEDFDB9F-595D-4FCB-A7EF-196A68513641Q35545648-3F365532-9EC2-4698-8E45-404331AC4127Q35679349-868F72EE-2448-4D3B-87A5-7A1D0DD838AFQ35749307-AA8C179D-0F6E-4509-9E4F-890D0BF112F0Q36280711-E5291A22-5817-4ACE-B843-DB3914535261Q37237619-58779A64-C846-48C5-9B6B-24ED77F2C0D2Q37262426-C587C234-BFDE-471E-AD32-DE66CEC729AEQ37281253-14ED73C6-F5DB-47A2-81DE-F6084096DCBAQ37315128-DD295F9C-6946-4F82-8E23-63CD6972ED53Q37577095-BE3D1877-6A28-4712-89B6-9A4EF9185BD5Q37582623-14F8A4EC-BF09-4C97-AEC8-F02765F88F7AQ38180319-9A67C340-40BC-436A-B426-308D0AD88C48Q38185688-D892EB70-F566-4459-8107-69066E318BB1
P2860
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Imatinib for melanomas harbori ...... d chronically sun-damaged skin
@ast
Imatinib for melanomas harbori ...... d chronically sun-damaged skin
@en
Imatinib for melanomas harbori ...... chronically sun-damaged skin.
@nl
type
label
Imatinib for melanomas harbori ...... d chronically sun-damaged skin
@ast
Imatinib for melanomas harbori ...... d chronically sun-damaged skin
@en
Imatinib for melanomas harbori ...... chronically sun-damaged skin.
@nl
altLabel
Imatinib for Melanomas Harbori ...... d Chronically Sun-Damaged Skin
@en
prefLabel
Imatinib for melanomas harbori ...... d chronically sun-damaged skin
@ast
Imatinib for melanomas harbori ...... d chronically sun-damaged skin
@en
Imatinib for melanomas harbori ...... chronically sun-damaged skin.
@nl
P2093
P2860
P3181
P356
P1476
Imatinib for melanomas harbori ...... d chronically sun-damaged skin
@en
P2093
Adrian Marino-Enriquez
Anita Giobbie-Hurder
Annick D Van den Abbeele
Carol Beadling
Christopher L Corless
David E Fisher
Donald Lawrence
F Stephen Hodi
Frances A Collichio
George D Demetri
P2860
P304
P3181
P356
10.1200/JCO.2012.47.7836
P407
P577
2013-09-10T00:00:00Z